Gastroenterology

  • PENTASA®
    PENTASA®
    (mesalazine)
    (mesalazine)

    Gastroenterology
  • PENTASA® (mesalazine)

    PENTASA® (mesalazine) is Ferring's product used for the treatment and long-term management of inflammatory bowel diseases (IBD) (Ulcerative colitis and Crohn's disease).

    PENTASA is prescribed to treat the mild to moderate symptoms of active IBD as well as being used widely as maintenance therapy to reduce the risk of recurrent attacks.

    PENTASA is available orally as tablets and granules (sachets) within Europe and the rest of the world, excluding the USA. In the USA, Shire US, Inc. sells PENTASA under a trademark license from Ferring. Topical formulations (suppositories and enemas) are also available for administration via the rectum, allowing a high concentration of the drug to be in contact with areas of inflammation at the lower end of the digestive tract.

    Oral PENTASA has a prolonged-release formulation, helping to ensure release of active mesalazine throughout the entire length of the intestine from the duodenum to the rectum. Topical PENTASA formulations (enemas and suppositories) enable active mesalazine to remain in contact with the inflamed mucosa for several hours.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner

  • PICOPREP®
    PICOPREP®
    (sodium picosulphate, magnesium oxide, citric acid)
    (sodium picosulphate, magnesium oxide, citric acid)

    PICO-SALAX® / PICOLAX® / PREPOPIK®

    Gastroenterology
  • PICOPREP® (sodium picosulphate, magnesium oxide, citric acid)

    PICOPREP® (sodium picosulphate, magnesium oxide, citric acid) is indicated to clean the bowel prior to X-ray examination or endoscopy, to clean the bowel prior to surgery when judged clinically necessary. PICOPREP® has approved dosing for children as of 1 year old and adults.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner

  • GLYPRESSIN®
    GLYPRESSIN®
    (terlipressin)
    (terlipressin)

    Gastroenterology
  • GLYPRESSIN® (terlipressin)

    GLYPRESSIN (terlipressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1.

    GLYPRESSIN is administered to patients by the healthcare professional giving an injection directly into a vein.

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner

  • CORTIMENT®MMX®
    CORTIMENT®MMX®
    (budesonide)
    (budesonide)

    Gastroenterology
  • CORTIMENT®MMX® (budesonide)

    CORTIMENT®MMX® (budesonide)* is indicated in adults for induction of remission in patients with active mild-to-moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not sufficient.

    CORTIMENT®MMX® contains budesonide, a locally acting glucocorticosteroid, in a novel, patented, oral tablet formulation utilizing MMX® multimatrix colonic delivery technology that is designed to result in the controlled release and distribution of budesonide throughout the length of the colon.

    (*CORTIMENT®MMX® has been developed by Cosmo Pharmaceuticals S.A. Ferring is the licensee in the EU and Asia (excluding Japan), Australia, Canada, Latin America and Africa. In the United States, where the product is available as UCERIS®, the licensee is Salix Pharmaceuticals, Inc.

    CORTIMENT is a trademark of Ferring B.V. MMX is a trademark of Cosmo Pharmaceuticals S.A. UCERIS is a registered trademark of Santarus, Inc, a wholly owned subsidiary of Salix Pharmaceuticals, Inc.)

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.

Headquarters

Ferring International Center S.A.
Ch. de la Vergognausaz 50
1162 Saint-Prex
Switzerland

Tel:  +41 58 301 00 00
Fax: +41 58 301 00 10

Contact

GLOBAL LOCATOR